Rain Oncology Inc.
Rain Oncology Inc. (RAIN): 2 pipeline candidates · ~33 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
32.7 months
D/E 0.22 · 0% dilution
Lead: Phase 3
2 candidates
N/A
N/A
A transparent, data-derived signal for Rain Oncology Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$21.1M
Cash
$37.3M
Quarterly Burn
$7.0M
Runway
32.7 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| milademetan | Phase 3 |
| rad52 inhibitor | Preclinical |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
12
Total value held
$2.2M
| Holder | Shares | Value |
|---|---|---|
| meteora capital, llc | 638,287 | $1.6M |
| knott david m jr | 101,686 | $258K |
| vanguard capital management llc | 79,286 | $201K |
| geode capital management, llc | 30,538 | $78K |
| vanguard fiduciary trust co | 17,159 | $44K |
| jpmorgan chase & co | 8,290 | $22K |
| blackrock, inc. | 4,609 | $12K |
| royal bank of canada | 1,789 | $5K |
| tower research capital llc (trc) | 1,202 | $3K |
| morgan stanley | 950 | $2K |
Showing top 10 of 12 institutional holders of Rain Oncology Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Rain Oncology Inc.'s pipeline?
Rain Oncology Inc. (RAIN) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Rain Oncology Inc.'s lead drug candidate?
Rain Oncology Inc.'s most advanced tracked candidate is milademetan (Phase 3) for Merkel cell carcinoma (MCC).
What is Rain Oncology Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Rain Oncology Inc. has approximately 32.7 months of cash runway.
What is Rain Oncology Inc.'s market capitalization?
Rain Oncology Inc.'s market capitalization is approximately $21.1M.
Who is the CEO of Rain Oncology Inc.?
Mr. Randall P. Seidl is the chief executive officer of Rain Oncology Inc. (RAIN).
Get the full picture on Rain Oncology Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.